EPO Patents = 1

Forward Citations = 0

Loading Chart...

14 inventors (with patents filed for the assignee):

Hergen Spits (4 out of 25 patents)

Paula Maria Wilhelmina Van Helden (3 out of 4 patents)

Wouter Pos (2 out of 3 patents)

4. Marijn Aletta Gillissen (2 out of 3 patents)

5. Mette Deborah Hazenberg (2 out of 3 patents)

6. Martijn Kedde (2 out of 3 patents)

7. Tim Beaumont (2 out of 29 patents)

8. Remko Schotte (1 out of 3 patents)

9. Christien Fatmawati (1 out of 2 patents)

10. Danïel Michiel Go (1 out of 2 patents)

11. Julien Christian Villaudy (1 out of 2 patents)

12. Koen Wagner (1 out of 5 patents)

13. Mark Jeroen Kwakkenbos (1 out of 17 patents)

14. Adrianus Quirinus Bakker (1 out of 16 patents)

15. Hergen Spits (0 patent)

4 patents: Sort by Forward Citations

1. 12084681 - Ex vivo antibody production (2024-09-10),

2. 11999793 - Therapeutic anti-CD9 antibody (2024-06-04),

3. 11629200 - Means and methods for counteracting myeloproliferative or lymphoproliferative disorders (2023-04-18),

4. 11524989 - AML antigens and uses thereof (2022-12-13),

Kling Biotherapeutics B.v. is a biotechnology company dedicated to developing innovative therapies for cancer. Our team of experts is focused on advancing cutting-edge research in immuno-oncology to improve patient outcomes. With a passion for science and a commitment to excellence, Kling Biotherapeutics is driven to make a meaningful impact in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

4 Patents

#117 in Amsterdam

#1,302 in Netherlands

Amsterdam, Netherlands

Kling Biotherapeutics B.v.